European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
“Fuzzy” radiomics: the way forward for nuclear medicine imaging applications?	340
Towards molecular imaging-guided intervention theatres in oncology	234
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis	180
Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands	167
A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients	133
FAPI PET/CT in infectious, inflammatory, and rheumatological diseases: “watch it like a hawk” or “one swallow does not make a summer”?	120
Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma	118
New horizons for the World Federation of Nuclear Medicine and Biology: achievements, partnerships, and future directions	98
Real-time diagnosis of sampled lesions in targeted biopsy of prostate Cancer using a novel tracer [64Cu] Cu-DOTA-PSMA-3Q: a pilot preclinical study	95
[18F]Fluorocholine PET/MRI and [18F]Fluorocholine PET/CT as first- and second-line imaging in primary hyperparathyroidism – who takes the lead?	91
Cadherin-17 as a target for the immunoPET of adenocarcinoma	87
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer	80
PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study	78
Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT: A quantitative imaging study with implications for cardiovascular risk	78
Nuclear imaging and therapy in oncology in Poland in 2021–2022	74
FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study	68
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review	60
Correction to: Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme	60
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangli	58
Combination therapy of an 211At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy	58
Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard	52
Sex-specific differences in patients with differentiated thyroid carcinoma and their possible impact on survival	52
Tracking macrophages by direct and indirect 89Zr PET imaging	51
Long-term impact of myocardial inflammation on quantitative myocardial perfusion—a descriptive PET/MR myocarditis study	51
Preclinical development of [18F]TAAR1-2203 as a PET radioligand for imaging TAAR1 expression and receptor occupancy	50

Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer – Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/C	50
Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer	50
Bone matters: Ga-68 PSMA PET/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [¹⁷⁷Lu]Lu-PSMA-617	49
[68Ga]Ga-FAPI versus [18F]FDG PET/CT in the evaluation of Langerhans cell histiocytosis	49
Dynamic frame-by-frame motion correction for 18F-flurpiridaz PET-MPI using convolution neural network	49
Enhancing interpretability of AI with radiomics-based deep neural network: proof of concept in the classification of Parkinsonian syndromes with 18F-FDG PET imaging	49
The feasibility of quantitative assessment of dynamic 18F-fluorodeoxyglucose PET in Takayasu’s arteritis: a pilot study	48
Cinematic rendering of [18F]FDG-PET/MR	48
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2	48
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)	48
68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy	47
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus	47
Robust and generalizable artificial intelligence for multi-organ segmentation in ultra-low-dose total-body PET imaging: a multi-center and cross-tracer study	47
[18F]FDG PET/MR to assess disease extension and inflammation in children and young adults with primary ciliary dyskinesia	47
Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group	46
Brain perfusion estimation by Tikhonov model-free deconvolution in a long axial field of view PET/CT scanner exploring five different PET tracers	46
Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation	46
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	46
Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement	45
Seasonal variation in D2/3 dopamine receptor availability in the human brain	45
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer	44
Avid 18F-FDG uptake of benign gastric-type intraductal papillary mucinous neoplasm of the pancreas	44
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial	44
Simultaneous high-resolution whole-brain MR spectroscopy and [18F]FDG PET for temporal lobe epilepsy	44
Deep learning–based whole-body characterization of prostate cancer lesions on [68Ga]Ga-PSMA-11 PET/CT in patients with post-prostatectomy recurrence	42
Abdelhamid H. Elgazzar, Synopsis of Pathophysiology in Nuclear Medicine, Second Edition	42
Assessment of [18F]PI-2620 Tau-PET Quantification via Non-Invasive Automatized Image Derived Input Function	42
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)	42
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis	42
Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma	42
Diffusely increased breast uptake of [18F]AlF-NOTA-FAPI-04 related to menstrual status in a patient with papillary thyroid cancer	41
Lisa Bodei, Jason S. Lewis, Brian M. Zeglis (Editors): Radiopharmaceutical Therapy	41
Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children	40
Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study	40
Bilateral intense [68 Ga]Ga-PSMA‑11 uptake in cyproterone acetate induced gynecomastia	40
Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia	40
Multi-modality deep learning-based [68Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction	40
[68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed	39
Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression	39
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography	39
Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging	39
An artificial intelligence-driven image quality assessment system for whole-body [18F]FDG PET/CT	39
Preclinical evaluation and pilot clinical study of [68Ga]Ga-NOTA-H006 for non-invasive PET imaging of 5T4 oncofetal antigen	39
Comparison of two hybrid sentinel node tracers: indocyanine green (ICG)-99mTc-nanocolloid vs. ICG-99mTc-nanoscan from a nuclear medicine and surgical perspective	39
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgk	39
A distinctive “Shotgun-like” 18F-FDG PET uptake pattern in disseminated cutaneous sarcoidosis responding to TNFα inhibitors	38
Parkinson’s Disease-Related pattern in isolated REM sleep behaviour disorder as a prodromal progression marker: 8-Year Follow-Up changes assessed at three time points	38
[18F]-mFBG imaging for COVID-19-induced cardiac sympathetic innervation impairment	38
Atypical [18F]FDG avidity in ALK-positive anaplastic large cell lymphoma: diagnostic and monitoring potential of [18F]FAPI PET/CT	38
About ESTMABLE2: non-inferiority doesn’t equal better	38

Moganshan international consensus on further strengthening global scientific collaboration in the field of molecular imaging	37
A cutting-edge technology for the future of nuclear medicine	37
Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	37
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake	37
Intense [68Ga]Ga-FAPI-04 uptake of pancreatic microcystic serous cystadenoma mimicking malignancy	37
Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review	37
Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?	37
[68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma	36
Imaging biomarkers of cortical neurodegeneration underlying cognitive impairment in Parkinson’s disease	36
Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease	36
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer	36
[68Ga]Ga-NOTA-T4 ImmunoPET imaging for evaluating TROP2 expression in patients with solid tumors	36
Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study	36
STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy	35
Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study	35
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study	35
[68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11	35
Promise of hypoxia-targeted tracers in metastatic lymph node imaging	35
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients	35
Differential Vascular Response to Corticosteroid Therapy in Takayasu Arteritis Revealed by Serial FDG-PET Imaging	35
Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis	34
Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis	34
PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study	34
Correction to: A bis-boron boramino acid PET tracer for brain tumor diagnosis	33
Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993	33
Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms	33
Impact of extended [177Lu] Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?	33
Development of STING probes and visualization of STING in multiple tumor types	33
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging	33
Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy	33
Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective	33
Interpretable multimodal deep learning model for predicting post-surgical international society of urological pathology grade in primary prostate cancer	32
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)	32
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds	32
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside	32
Guiding principles on the education and practice of theranostics	32
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer	31
Distinct metabolic patterns of neuropsychiatric systemic lupus erythematosus on hierarchical cluster analysis	31
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios	31
Reply to Vaz et al., Editorial Commentary: Should “Heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?	31
Forearm metastasis as solitary manifestation of recurrent prostate cancer: A challenge for standard PSMA PET imaging protocol	31
A rationally designed nuclei-targeting FAPI 04-based molecular probe with enhanced tumor uptake for PET/CT and fluorescence imaging	31
Radioembolization of hepatocellular carcinoma with 90Y glass microspheres: an earlier administration day unexpectedly improves tumour control probability	31
PET/CT with [68Ga]Ga-TEoS-DAZA for localization of a traumatic biliary leak	31
European guidelines update on PSMA PET/CT for prostate cancer staging—snap back to reality	31
Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates	30
Correction to: [18F]FDG brain PET findings in CLIPPERS at diagnosis and therapeutic follow-up	30
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging	30
[99mTc]Tc-sestamibi SPECT/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study)	30
Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study	30
Molecular imaging: The bridge from human phenome to personalized precision medicine	30
Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging	30
Pre-symptomatic scintigraphic and genetic cascade screening in cardiac transthyretin amyloidosis	30
Correction to: Deep learning for improving PET/CT attenuation correction by elastic registration of anatomical data	30
Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts	30
Comparison of the diagnostic value of [68 Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in patients with T stage ≤ 2a2 uterine cervical cancer: a prospective study	30
Association of PET vascular activity score with Takayasu’s arteritis angiographic progression	29
The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir	29
Bone marrow scintigraphy as a prognostic marker of overall survival in mCRPC patients treated with Radium-223 dichloride	29
The first international network symposium on artificial intelligence and informatics in nuclear medicine: “The bright future of nuclear medicine is illuminated by artificial intelligence”	29
A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer	29
Visual grading for noninvasive assessment of transthyretin-related cardiomyopathy with bone scintigraphy: time for moving forward?	29
Longitudinal renal function following [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer	28
¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT	28
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease	28
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study	28
Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry	28
Assessing non-invasive quantitative methods for [18F]SynVesT-1 PET imaging of synaptic vesicle glycoprotein 2A in the rat brain	28
Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models	28
Exploring the value of FAP-targeted PET/CT in differentiating breast cancer molecular subtypes: a preliminary study	28
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy	28
Targeted alpha therapy: a comprehensive analysis of the biological effects from “local-regional-systemic” dimensions	28
[177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach	28
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	28
Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma	28
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation	28
Multicentric development and evaluation of [18F]FDG PET/CT and CT radiomic models to predict regional and/or distant recurrence in early-stage non-small cell lung cancer treated by stereotactic body r	28
Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images	27
PET imaging of new target CDK19 in prostate cancer	27
Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging	27

Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues	27
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success	27
Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy	27
Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST	27
Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas	27
Comparison of mCRPC [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting	26
First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm	26
Pyomyositis, a rare complication of a urinary tract infection on FDG PET/CT	26
Personalised PET imaging in oncology: an umbrella review of meta-analyses to guide the appropriate radiopharmaceutical choice and indication	26
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study	26
CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology	26
PET imaging utilization and trends in Germany: a comprehensive survey	26
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications	26
Intelligent ultrafast total-body PET for sedation-free pediatric [18F]FDG imaging	26
Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer	26
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study	26
Clinical added value of LAFOV PET/CT in patients undergoing same-day [18 F]FDG SAFOV PET/CT scans: an initial experience report and explorative study	26
Impact of Tafamidis on [99mTc]Tc-pyrophosphate Scintigraphy in Ala97Ser Hereditary Transthyretin amyloid cardiomyopathy: significant initial reduction with stable Long-Term effects	25
Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?	25
The eye-black sign of lower eyelids related to R-CHOP therapy: a rare imaging pitfall	25
PET imaging of animal models with depressive-like phenotypes	25
Prognostic role of metabolic parameters (MTV and TLG) of staging PET/CT in the pediatric population with Hodgkin’s lymphoma: an open discussion	25
Intraprocedural MRI-based dosimetry during transarterial radioembolization of liver tumours with holmium-166 microspheres (EMERITUS-1): a phase I trial towards adaptive, image-controlled treatment del	25
18F-sodium fluoride PET-CT visualizes both axial and peripheral new bone formation in psoriatic arthritis patients	25
Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study	25
Extended nodal radiotherapy for prostate cancer relapse guided with [11C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial	25
Collection on molecular imaging in cardiac amyloidosis	25
PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers	25
Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?	25
Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics	25
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis	24
DICOM header editing, between possibilities and regulatory bounds– 40 years of DICOM “standard”	24
Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature	24
PET scout: A valuable technology in pediatric 18F-FDG PET/CT imaging	24
Expert consensus on workflow of PET/CT with long axial field-of-view	24
Correction to: Modelling [18F]LW223 PET data using simplified imaging protocols for quantification of TSPO expression in the rat heart and brain	24
Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT	24
Comprehensive analysis of [18F]MFBG biodistribution normal patterns and variability in pediatric patients with neuroblastoma	24
Bridging the gap to clinical translation: the advanced role of PET molecular imaging in stem cell therapy	24
Correction to: Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate	24
The value of serial [⁶⁸Ga]Ga-FAPI-04 PET/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer	24
PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington’s disease	24
Rapid dynamic acquisition of cardiac amyloid radionuclide imaging	23
Neoadjuvant alpha peptide receptor radionuclide therapy for a patient with a pulmonary carcinoid	23
Pleasurable music activates cerebral µ-opioid receptors: a combined PET-fMRI study	23
Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis	23
Interpretive consistency of a qualitative 68Ga-PSMA PET framework for treatment response assessment in hepatocellular carcinoma: a head-to-head comparison with cross-sectional imaging	23
Targeting tumour surface collage with hydrogel probe: a new strategy to enhance intraoperative imaging sensitivity and stability of bladder cancer	23
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer	23
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI	23
The confounding effects of microvascular physiology on the uptake and diagnostic accuracy of [18F]fluoroethyl-tyrosine positron emission tomography in gliomas	22
Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020	22
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology	22
Exploring the metabolic landscape of lung adenocarcinoma and squamous cell carcinoma: a total-body [18F]FDG PET/CT approach	22
Role of brain 2-[18F]fluoro-2-deoxy-D-glucose-positron-emission tomography as survival predictor in amyotrophic lateral sclerosis	22
Remarkable response after cocktail therapy with 177Lu-PSMA and 177Lu-DOTA-IBA in the treatment of mCRPC	22
Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis	22
Subendocardial quantification enhances coronary artery disease detection in 18F-flurpiridaz PET	22
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy	22
Fully automated spleen segmentation predicts progression-free survival in HCC patients following transarterial radioembolization	22
Multidisciplinary team interpretation performance for indeterminate bone uptake on PSMA PET during prostate cancer staging: Comparison with PROMISE criteria	22
New thresholds in semi-quantitative [18F]FDG PET/CT are needed to assess large vessel vasculitis with long-axial field-of-view scanners	22
The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis	22
In vivo methods for imaging blood–brain barrier function and dysfunction	22
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study	21
Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles	21
L.J. Koenig, D. Tamimi, S.E. Perschbacher, H. Demirturk. Diagnostic imaging: oral and maxillofacial. 3rd Edition	21
The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study	21
Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma	21
Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies	21
Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols	21
The role of radiographers in nuclear medicine; the link between patient and technology	21
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours	21
Preoperative assessment of pancreatic cancer with [68Ga]Ga-DOTA-FAPI-04 PET/MR versus [18F]-FDG PET/CT plus contrast-enhanced CT: a prospective preliminary study	21
Lymph node classification in E-PSMA reporting guidelines for PSMA-PET	21
Total-body pediatric PET is ready for prime time	21
Connectivity based on glucose dynamics reveals exaggerated sensorimotor network coupling on subject-level in Parkinson’s disease	20
Letter to the Editor: Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer	20
Image fraud in nuclear medicine research	20
Correction to: Hetero-bivalent agents targeting FAP and PSMA	20
The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica—a prospective study of 101 patients	20
A network analysis of whole-body [18F]FDG PET/CT reveals glycaemia-associated reorganization of systemic metabolic coordination	20
[177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data	20
New opportunities for dosimetric approach in patients with differentiated thyroid cancer	20
Pigmented villonodular synovitis detected by [68Ga]Ga-FAPI-04 PET/CT	20
Correction To: Coronary artery calcium measurement on attenuation correction computed tomography using artificial intelligence: correlation with coronary flow capacity and prognosis	20
Comparative evaluation of a novel [18F] F-Labeled PET tracer XTR004 against [13N] ammonia in myocardial perfusion imaging for coronary artery disease	20
Utilizing artificial intelligence to detect cardiac amyloidosis in patients with severe aortic stenosis: A step forward to diagnose the underdiagnosed	20
Positive amyloid and tau PET in an early-onset Alzheimer’s disease with a rare PSEN1 (Arg278Gly) mutation	20
Complications and outcomes of radioligand therapy in patients with neuroendocrine neoplasms depending on the baseline glomerular filtration rate	20
SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective	20
James F. Griffith. Diagnostic ultrasound: musculoskeletal, 3rd edition. Elsevier, 2025, ISBN: 9780443285646	20
99mTc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel	20
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China	20
FAP inhibitors: are we really using the best method to evaluate the residence time?	20